Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Thanatophoric dysplasia Indication Strategy Report 2026: FGFR3, Trials and Deals
24 July 2026
2026 Thanatophoric dysplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hypochondroplasia Indication Strategy Report 2026: FGFR3, Trials and Deals
24 July 2026
2026 Hypochondroplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Achondroplasia Indication Strategy Report 2026: FGFR3, Trials and Deals
24 July 2026
2026 Achondroplasia strategy: epidemiology, FGFR3 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Cleidocranial dysplasia Indication Strategy Report 2026: RUNX2, Trials and Deals
24 July 2026
2026 Cleidocranial dysplasia strategy: epidemiology, RUNX2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Pycnodysostosis Indication Strategy Report 2026: CTSK, Trials and Deals
24 July 2026
2026 Pycnodysostosis strategy: epidemiology, CTSK biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Osteopetrosis Indication Strategy Report 2026: RANKL, Trials and Deals
24 July 2026
2026 Osteopetrosis strategy: epidemiology, RANKL biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Mitochondrial neurogastrointestinal encephalomyopathy Indication Strategy Report 2026: TYMP, Trials and Deals
24 July 2026
2026 Mitochondrial neurogastrointestinal encephalomyopathy strategy: epidemiology, TYMP biology, clinical competition, recent deals, unmet need and market…
Latest Hotspot
8 min read
NARP syndrome Indication Strategy Report 2026: MT-ATP6, Trials and Deals
24 July 2026
2026 NARP syndrome strategy: epidemiology, MT-ATP6 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Kearns-Sayre syndrome Indication Strategy Report 2026: Mitochondrial DNA, Trials and Deals
24 July 2026
2026 Kearns-Sayre syndrome strategy: epidemiology, Mitochondrial DNA biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
LCAT deficiency Indication Strategy Report 2026: LCAT, Trials and Deals
24 July 2026
2026 LCAT deficiency strategy: epidemiology, LCAT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Tangier disease Indication Strategy Report 2026: ABCA1, Trials and Deals
24 July 2026
2026 Tangier disease strategy: epidemiology, ABCA1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Abetalipoproteinemia Indication Strategy Report 2026: MTTP, Trials and Deals
24 July 2026
2026 Abetalipoproteinemia strategy: epidemiology, MTTP biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…